Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
0.8900
-0.0299 (-3.25%)
Jul 16, 2026, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 25 employees as of March 31, 2026. The number of employees did not change since the number was last reported on December 31, 2025.
Employees
25
Change
n/a
Growth
n/a
Revenue / Employee
$3,600
Profits / Employee
-$938,840
Market Cap
27.92M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 25 | 0 | - |
| Dec 31, 2025 | 25 | -12 | -32.43% |
| Dec 31, 2024 | 37 | -12 | -24.49% |
| Dec 31, 2023 | 49 | 0 | - |
| Dec 31, 2022 | 49 | 17 | 53.13% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Evaxion | 46 |
| Senti Biosciences Holdings | 39 |
| Kyntra Bio | 34 |
| Plus Therapeutics | 28 |
| NeuroSense Therapeutics | 17 |
| Barinthus Biotherapeutics | 14 |
| Tvardi Therapeutics | 12 |
ATNM News
- 6 weeks ago - Actinium Pharmaceuticals Slides: Investor presentation - Filings
- 6 weeks ago - Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026 - TheFly
- 6 weeks ago - Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer - PRNewsWire
- 6 weeks ago - Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models - PRNewsWire
- 6 weeks ago - Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer - TheFly
- 6 weeks ago - Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development - PRNewsWire
- 6 weeks ago - Actinium Pharmaceuticals presents new radiochemistry data at SNMMI - TheFly
- 6 weeks ago - Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates - PRNewsWire